Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2024 Earnings Call Transcript May 9, 2024 Lisata Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Lisata Therapeutics First Quarter 2024 Financial Results and Business Update Conference Call. At this […]
The FDA bestows an Orphan Drug designation to Lisata's (LSTA) lead investigational product candidate, LSTA1, for the treatment of osteosarcoma. Stock rises.
Lisata's (LSTA) lead investigational product candidate, LSTA1, gets Rare Pediatric Disease Designation for treating osteosarcoma. Stock rises.